Bacitracin is a polypeptide antibiotic primarily used in topical formulations to prevent and treat minor skin infections. It is derived from Bacillus subtilis and works by inhibiting bacterial cell wall synthesis, making it effective against a range of Gram-positive bacteria, including Staphylococcus and Streptococcus species.

Due to its mechanism of action, Bacitracin is often utilized in compounded formulations for its potent antibacterial properties, especially in cases where localized treatment is necessary. Its use is particularly advantageous in patients who may be allergic to other antibiotics, as it is less likely to cause systemic allergic reactions.

In clinical practice, Bacitracin is valued for its minimal systemic absorption when applied topically, reducing the risk of systemic toxicity. This makes it a preferred choice for treating superficial skin infections, wounds, and surgical incisions, where localized antibacterial action is desired without significant systemic exposure.

Prescribers should be aware that while Bacitracin is effective against many Gram-positive organisms, it is not effective against Gram-negative bacteria or fungi. Therefore, it is crucial to consider the specific microbial flora involved in an infection when selecting Bacitracin as a treatment option.

Additionally, Bacitracin is often compounded with other active ingredients to enhance its therapeutic efficacy or to target a broader spectrum of pathogens. This flexibility in compounding allows for tailored formulations that meet the specific needs of individual patients, optimizing therapeutic outcomes.